Daxor Corporation, known for its blood volume measurement technology, has launched a new service designed to drive faster adoption and provide greater prescriber access to Daxor’s blood volume analysis technology (BVA): ezBVA Lab Services.
Daxor’s ezBVA Lab is a state-of-the-art CLIA certified facility located at Daxor’s Oak Ridge, Tenn., facility that provides on-demand, next day blood volume analysis results. The lab is staffed by certified nuclear medicine technologists overseen by a board-certified medical director.
“This service allows customers at licensed hospitals and clinics to send patient blood samples to Daxor for 24-hour processing, lowering the labor, and the overhead required to conduct the test and deliver results,” says Jean Oertel, senior VP of commercialization. “We anticipate a quicker customer launch and shorter sales cycle at new accounts as a result of this streamlined process.”
“Daxor’s ezBVA Lab requires no capital investment from our customers while easily integrating into workflow with eligible reimbursement by both private and public insurance,” says Michael Feldschuh, CEO of Daxor Corporation. “We are excited to provide a simpler, cost-effective solution for hospitals and clinicians to adopt our technology who do not have our analyzer systems available in their lab but will instead utilize Daxor’s paid lab service, so providers can achieve optimal fluid management for their patients.”
About Daxor Corporation
Daxor Corporation is known for its blood volume measurement technology focused on blood volume testing innovation. The company developed and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the United States, enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care.
